DENV IgM ELISA Kit

Produktnummer ABIN1326831

Dieses Human DENV IgM ELISA-Kit ist ein Colorimetric ELISA-Kit, das dafür entwickelt wurde, Human DENV IgM zu quantifizieren. Dieses ELISA Kit wurde in 1 Publikation zitiert.

Kurzübersicht für DENV IgM ELISA Kit (ABIN1326831)

Target: DENV IgM (Dengue Virus Antibody IgM (DENV IgM))

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Proben: Serum

Produktdetails DENV IgM ELISA Kit

Verwendungszweck: Diluted patient serum (serum diluent contains sorbent to remove rheumatoid factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

Analytische Methode: Qualitative

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für DENV IgM ELISA Kit (ABIN1326831)

Navarrete-Espinosa, Cuervo-Hernández, Vázquez-Martínez: "[Hemorrhagic dengue without hemorrhaging: a novel diagnostic category?]." in: Gaceta médica de México, Vol. 144, Issue 2, pp. 105-10, (2008) (PubMed).

Details zu DENV IgM

Target: DENV IgM (Dengue Virus Antibody IgM (DENV IgM))

Andere Bezeichnung: Dengue Virus IgM

Substanzklasse: Antibody

Hintergrund: The mosquito-borne dengue viruses (serotype 1-4) cause dengue fever, a severe flu-like illness. The disease is prevalent in Third World tropical regions and spreading to sub-tropical developed countries - including the United States. WHO estimates that 50-80 million cases of dengue fever occur worldwide each year, including a potentially deadly form of the disease called dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Primary infection with color: blackdenguevirus results in a self-limiting disease characterized by mild to high fever lasting 3 to 7days, severe headache with pain behind the eyes, muscle and jointpain, rash and vomiting. Secondary infection is the more common form of the disease inmany parts of Southeast Asia and South America. This formof the disease is more serious and can result in DHF and DSS. The major clinical symptoms caninclude high fever, hemorrhagic events, and circulatory failure,and the fatality rate can be as high as 40%. Early diagnosis ofDSS is particularly important, as patients maydie within 12 to 24 h if appropriate treatment is not administered. Primary color: blackdengue virus infection is characterized by elevations in specific IgM antibody levels 3 to 5 days afterthe onset of symptoms this generally persists for 30 to 60 days. IgG levels also become elevated after 10 to 14 days and remain detectable for life. During secondaryinfection, IgM levels generally rise more slowly and reach lowerlevels than in primary infection, while IgG levels rise rapidlyfrom 1 to 2 days after the onset of symptoms